Harvard alumnus Omolivie Eboreime built a tiny Protein Nanoparticle that delivers CRISPR-based gene-editing tools straight into the body to treat blood diseases.
This skips the expensive, exhausting process of removing cells, editing them in a lab, and putting them back, a method that locks out low-income countries where sickle cell disease and beta-thalassemia hit hardest. These Hemoglobinopathies demand accessible solutions, yet current treatments remain out of reach for most.
Her design works like a smart delivery drone, finding the right cells and fixing the problem from within. She built a delivery system small enough to slip past biology’s barriers.
More than a technical feat, this nanoparticle embodies a philosophical shift: that the most sophisticated medicine should also be the most universal, reaching the very populations that stand to benefit most.
Article source: Africa Giant
